Table 1.

Characteristics of Female Survivors of European Ancestry in the SJLIFE Cohort

Characteristic	Survivors with subsequent BC	Survivors without subsequent BC
	N (%)	N (%)
Total	47	1086
Race
Non-Hispanic White	47 (100%)	1069 (98%)
Hispanic White	0 (0%)	13 (1%)
Other	0 (0%)	4 (0%)
Diagnosis
Leukemia
Acute lymphoblastic leukemia	3 (6%)	389 (36%)
Acute myeloid leukemia	2 (4%)	34 (3%)
Other leukemia	0 (0%)	1 (0%)
CNS tumors
Astrocytoma or glioma	1 (2%)	58 (5%)
Medulloblastoma or PNET	0 (0%)	22 (2%)
Ependymoma	0 (0%)	12 (1%)
Other	0 (0%)	21 (2%)
Lymphoma
Hodgkin lymphoma	30 (64%)	119 (11%)
Non-Hodgkin lymphoma	4 (9%)	52 (5%)
Sarcoma
Ewing sarcoma	0 (0%)	36 (3%)
Osteosarcoma	1 (2%)	37 (3%)
Rhabdomyosarcoma	0 (0%)	29 (3%)
Non-rhabdomyosarcoma	2 (4%)	33 (3%)
Embryonal
Wilms tumor	2 (4%)	89 (8%)
Neuroblastoma	0 (0%)	60 (6%)
Germ cell tumor	1 (2%)	25 (2%)
Other
Retinoblastoma	0 (0%)	28 (3%)
Hepatoblastoma	0 (0%)	6 (1%)
Melanoma	0 (0%)	5 (0%)
Carcinomas	1 (2%)	15 (1%)
Other	0 (0%)	15 (1%)
Radiation (%)
Any	40 (85%)	606 (56%)
Cranial radiation therapy	5 (11%)	345 (32%)
Breast	36 (77%)	149 (14%)
Pelvis	10 (21%)	187 (17%)
Chemotherapy
Alkylating agent	30 (64%)	597 (55%)
Anthracyclines	27 (57%)	636 (59%)
Epipodophyllotoxins	8 (17%)	408 (38%)
Mercaptopurine	5 (11%)	436 (40%)
Methotrexate	12 (26%)	548 (50%)
Platinum agents	2 (4%)	120 (11%)
Vinca alkaloids	34 (72%)	795 (73%)
Corticosteroids	17 (36%)	529 (49%)
	Median (range)	Median (range)
Age at diagnosis (years)	15.2 (3.1–21.2)	6.1 (0.01–22.7)
Age at follow-up (years)	44.5 (24.9–61.1)	35.0 (8.4–67.4)
Length of follow-up (years)	31.2 (13.4–51.2)	28.1 (5.6–53.5)